About
Antibodies and fragments
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyChina
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
163
By Phase
PHASE1: 3
By Status
COMPLETED: 2UNKNOWN: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT05824663Lead Sponsor
A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors
PHASE1Unknown
50 participants
Started: May 31, 2023 · Completed: Jun 30, 2025
NCT05306444Lead Sponsor
CLN-418 Study on Subjects With Advanced Solid Tumors
PHASE1Completed
48 participants
Started: May 12, 2022 · Completed: Sep 10, 2024
NCT04135261Lead Sponsor
A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors
PHASE1Completed
65 participants
Started: Sep 24, 2019 · Completed: Feb 15, 2023
Locations (1)
Headquarters
Shanghai, China
Map
Loading map...